University of Georgia
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Tag: Trypanosoma cruzi

Calcium-sensitive pyruvate dehydrogenase phosphatase is required for energy metabolism, growth, differentiation, and infectivity of Trypanosoma cruzi

Donna Huber on September 19, 2018

Abstract In vertebrate cells, mitochondrial Ca2+ uptake by the mitochondrial calcium uniporter (MCU) leads to Ca2+-mediated stimulation of an intramitochondrial pyruvate dehydrogenase phosphatase (PDP). This enzyme dephosphorylates serine residues in the E1α subunit of pyruvate dehydrogenase (PDH), thereby activating PDH and resulting in increased ATP production. Although a phosphorylation–dephosphorylation cycle for the E1α subunit of …

Trainee Spotlight: Ciro Cordeiro

Donna Huber on August 3, 2018

  Dr. Ciro D. Cordeiro recently completed his Ph.D. training in Roberto Docampo‘s laboratory. I was born in Brazil and grew up in a small city in the heart of the country, a place of great natural beauty dominated by savannas and agriculture. I have always been fascinated by nature and curious about all forms …

Study reveals key cause of treatment failure in Chagas disease

Donna Huber on March 29, 2018

Researchers at the University of Georgia have discovered that dormancy of the parasite Trypanosoma cruzi prevents effective drug treatment for Chagas disease, which kills more than 50,000 people each year in Central and South America and is a growing threat in the United States and Europe. The disease infects an estimated 6 million to 7 million …

Trainee Spotlight: Molly Bunkofse

Donna Huber on January 4, 2018

NIH T32 trainee Molly Bunkofse, a Ph.D. student in Rick Tarleton‘s laboratory, is originally from Illinois and I obtained my BA in Biology from a small, liberal arts college called Augustana, which is located in Rock Island, IL. Molly’s research focus Molly’s project focuses on the host CD8+ T cell response that is generated against …

UGA researchers to develop new treatment for Chagas disease

Donna Huber on January 28, 2015

Athens, Ga. – University of Georgia researchers in collaboration with Anacor Pharmaceuticals have received a $5.3 million grant from the Wellcome Trust to develop a new drug for the treatment of Chagas disease, which they hope will be ready to enter clinical trials by 2016. Chagas disease is caused by the parasite Trypanosoma cruzi, which …

Wellcome Trust funds Chagas disease drug discovery project

ovprweb on January 28, 2015

Dr. Rick Tarleton, in collaboration with Anacor Pharmaceuticals, was successful in having their Chagas disease drug discovery project funded by the Wellcome Trust. The objective of the project is to deliver a new drug candidate ready to enter clinical trials by 2016.